Get the Stockscreener App
1.61
6.94%
-0.12
After Hours:
1.64
0.03
+1.86%
Inhibikase Therapeutics Inc stock is traded at $1.61, with a volume of 1.72M.
It is down -6.94% in the last 24 hours and down -12.02% over the past month.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
See More
Previous Close:
$1.73
Open:
$1.73
24h Volume:
1.72M
Relative Volume:
0.91
Market Cap:
$212.57M
Revenue:
$79,600
Net Income/Loss:
$-48.26M
P/E Ratio:
-3.271
EPS:
-0.4922
Net Cash Flow:
$-28.24M
1W Performance:
-20.69%
1M Performance:
-12.02%
6M Performance:
+0.63%
1Y Performance:
-19.90%
1-Day Range:
$1.57
$1.77
1-Week Range:
$1.57
$2.04
52-Week Range:
$1.33
$2.26
Inhibikase Therapeutics Inc Stock (IKT) Company Profile
Name
Inhibikase Therapeutics Inc
Sector
Industry
Phone
(302) 295-3800
Address
1000 N. WEST STREET, SUITE 1200, WILMINGTON
Compare IKT vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IKT
Inhibikase Therapeutics Inc
|
1.61 | 228.42M | 79,600 | -48.26M | -28.24M | -0.4922 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 110.90B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
629.68 | 73.20B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.26 | 49.71B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
286.27 | 38.32B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
144.37 | 30.97B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inhibikase Therapeutics Inc Stock (IKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-26 | Initiated | Ladenburg Thalmann | Buy |
| Jan-21-26 | Initiated | BofA Securities | Buy |
| Dec-26-25 | Initiated | H.C. Wainwright | Buy |
| Dec-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-12-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
Inhibikase Therapeutics Inc Stock (IKT) Latest News
BofA Securities Maintains Inhibikase Therapeutics(IKT.US) With Buy Rating, Maintains Target Price $6 - Moomoo
ADAR1 reports 9.9% stake in Inhibikase (NASDAQ: IKT) via managed accounts - Stock Titan
Trails Edge holds 8.06M Inhibikase shares — Trails Edge (NASDAQ: IKT) - Stock Titan
Commodore Capital (IKT) reports 14.05M shares equivalent, 9.9% cap - Stock Titan
Perceptive Advisors/Perceptive Life Sciences disclose 8.9% holding in IKT (IKT) - Stock Titan
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
IKT Technical Analysis | Trend, Signals & Chart Patterns | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Analyst Flags High Risk in Inhibikase Therapeutics Stock, Urges Investors to Review 2025 Form 10-K Risk Factors - TipRanks
Is Inhibikase Therapeutics (IKT) Fairly Valued After Q1 2026 EPS - GuruFocus
Inhibikase Advances PAH Drug with Global Phase 3 Trial Launch - BriefGlance
Inhibikase Therapeutics Inc (NASDAQ:IKT) Reports Q1 2026 Results as Phase 3 PAH Trial Gains Momentum - ChartMill
Inhibikase Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Inhibikase (NASDAQ: IKT) deepens Q1 loss as pivotal PAH trial advances globally - Stock Titan
Inhibikase Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
INHIBIKASE THERAPEUTICS ($IKT) Releases Q1 2026 Earnings - Quiver Quantitative
Inhibikase (NASDAQ: IKT) advances IMPROVE-PAH as Q1 2026 loss widens - Stock Titan
Inhibikase Therapeutics Announces First Quarter 2026 Financial Results and Highlights Recent Activity - The Manila Times
Inhibikase Therapeutics 宣佈2026年第一季度財務業績並重點介紹近期活動 - Moomoo
Inhibikase Advances IKT-001 Into Adaptive Phase 3 Trial for Pulmonary Arterial Hypertension - TipRanks
Top Inhibikase Therapeutics (IKT) Competitors 2026 - MarketBeat
What XXxs fundamentals reveal about its future (Rallies) 2026-05-08AI Powered Stock Picks - newser.com
Inhibikase Therapeutics Inc expected to post a loss of 11 cents a shareEarnings Preview - TradingView
How Inhibikase Therapeutics (IKT) is navigating logistics challenges | Q4 2025: EPS Tops ViewsPro Trader Recommendations - newser.com
Inhibikase Therapeutics, Inc. (NASDAQ:IKT) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
IKT Inhibikase Therapeutics beats Q4 2025 loss estimates, shares post modest gains following earnings release.Strategic Review - newser.com
[DEF 14A] Inhibikase Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
[ARS] Inhibikase Therapeutics, Inc. SEC Filing - Stock Titan
Inhibikase Therapeutics | ARS: Annual Report to Security Holders - Moomoo
Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossSpecial Dividend - newser.com
Is Inhibikase Therapeutics (IKT) stock reversing trend | Inhibikase Therapeutics notches 13.6% EPS beat on narrower lossConsensus Beat - newser.com
IKT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Inhibikase Therapeutics (IKT) asks shareholders to add 3M plan shares - Stock Titan
Inhibikase enrolls first patient in phase 3 PAH trial - MSN
Inhibikase Therapeutics (IKT) Stock Trading Today (+7.65%) 2026-04-18Crowd Consensus Signals - Cổng thông tin điện tử tỉnh Lào Cai
Inhibikase Therapeutics | SCHEDULE 13G/A: Others - Moomoo
Inhibikase Enrolls First Patient in Phase 3 PAH Trial - MyChesCo
Inhibikase grants stock options to five new employees - MSN
What does insider activity suggest for Inhibikase Therapeutics (IKT) Stock | Price at $1.76, Up 3.53%Fibonacci Analysis - newser.com
First patient enrolled in Phase 3 trial of PAH treatment IKT-001 - Pulmonary Hypertension News
MACD Signal: What is the Moat Score of Inhibikase Therapeutics IncQuarterly Growth Report & Short-Term High Return Ideas - baoquankhu1.vn
IKT Stock Price, Quote & Chart | INHIBIKASE THERAPEUTICS INC (NASDAQ:IKT) - ChartMill
Inhibikase Grants Stock Options to Five New Employees - MyChesCo
H.C. Wainwright reiterates Inhibikase stock rating on trial progress By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Inhibikase stock rating on trial progress - Investing.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension - Sahm
Inhibikase Therapeutics Begins Enrollment for PAH Drug Trial - National Today
Inhibikase Therapeutics Enrolls First Patient in Global Phase 3 IMPROVE-PAH Study for Pulmonary Arterial Hypertension Treatment 1 - Minichart
Inhibikase enrolls first patient in Phase 3 PAH drug trial By Investing.com - Investing.com South Africa
Inhibikase Therapeutics Inc Stock (IKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):